Ranking Profile - Aurinia Pharmaceuticals Inc

Introduction

Aurinia Pharmaceuticals Inc (Aurinia Pharmaceuticals) is a commercial-stage biopharmaceutical company. The company pipeline product includes voclosporin, lupkynis, AUR200 and AUR300. Its lupkynis is an orally administered CNI immunosuppressant, to treat adult patients with active lupus nephritis. Aurinia Pharmaceuticals voclosporin is used in clinical studies in patients with psoriasis, kidney transplantation, uveitis and dry eye syndrome indications. The company's AUR300 reduces M2 dysregulation and decreases inflammatory cytokines and finds clinical applications for autoimmune and fibrotic diseases. It collaborates with Otsuka Pharmaceutical Co., Ltd for the development and commercialization of oral voclosporin. The company operates in Canada and the US. Aurinia Pharmaceuticals is headquartered in Victoria, British Columbia, Canada.